Compugen Ltd (CGEN) Quote

CGEN new 52 week hi

CGEN 10Q

Nice market reaction:
1.9100+0.1600 (+9.1429%)
As of 01:21PM EST. Market open.

Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer

https://finance.yahoo.com/news/compugen-receive-10-million-milestone-120500521.html

HOLON, Israel, Jan. 8, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that Compugen is entitled to receive a $10 million milestone payment from AstraZeneca (LSE/STO/Nasdaq: AZN), after the first patient was dosed in AstraZeneca's ARTEMIDE-Bil01 trial with rilvegostomig. Rilvegostomig is a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical-stage anti-TIGIT antibody, COM902. The ARTEMIDE-Bil01 trial is expected to recruit about 750 subjects in more than 20 countries with biliary tract cancer who will be randomized to receive rilvegostomig or placebo with investigator choice chemotherapy as adjuvant treatment after resection with curative intent.

"I am delighted to see the advancement of the rilvegostomig Phase 3 trial by AstraZeneca, a global leader in oncology, which has dosed the first patient triggering a $10 million milestone payment to Compugen," said Anat Cohen-Dayag, Ph.D., President, and Chief Executive Officer of Compugen. "Our license agreement with AstraZeneca is part of our strategy to broaden commercialization opportunities for our pipeline and specifically capitalize on the potentially emerging promise of bispecific therapies while maintaining our focus on the development of COM902 as part of the combination with COM701, our potential first-in-class anti-PVRIG antibody."

About the Compugen-AstraZeneca license agreement

In 2018, Compugen and AstraZeneca entered into an agreement by which Compugen provided an exclusive license to AstraZeneca to use Compugen's monospecific antibodies that bind to TIGIT, including COM902, for the development of bispecific and multispecific antibody products, excluding such bispecific and multispecific antibodies that also bind to PVRIG, PVRL2 and/or TIGIT. AstraZeneca is responsible for all research, development, and commercial activities. AstraZeneca has the right to create multiple products under this license. In addition to the $10 million milestone payment described in this press release, Compugen has received a $10 million upfront payment, and an additional $15.5 million in milestone payments to date, all out of up to an aggregate milestone amount of $200 million that the Company is eligible to receive in development, regulatory and commercial milestones for the first product, as well as tiered royalties on future product sales. If additional bi- or multi-specific therapies are developed based on Compugen's monospecific antibodies that bind to TIGIT, additional milestones and royalties would be due to Compugen.

Further details about ARTEMIDE-Bil01 trial are available on ClinicalTrials.gov, identifier: NCT06109779

About Compugen

Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has developed two proprietary product candidates: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Compugen also has a clinical stage partnered program, rilvegostomig (previously AZD2936), a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, of which the most advanced program, COM503, is in IND enabling studies is licenced to Gilead. COM503 is a potential first-in-class, high affinity antibody which blocks the interaction between IL-18 binding protein and IL-18, thereby freeing natural IL-18 in the tumor microenvironment to inhibit cancer growth. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.

Forward-Looking Statement

This press release contains "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended, and the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on the current beliefs, expectations, and assumptions of Compugen. Forward-looking statements can be identified using terminology such as "will," "may," "expects," "anticipates," "believes," "potential," "plan," "goal," "estimate," "likely," "should," "confident," and "intends," and similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include, but are not limited to, statements relating to the recruitment of subjects to the ARTEMIDE-Bil01 trial. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance, or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Among these risks: Compugen's business model is substantially dependent on entering into collaboration agreements with third parties and Compugen may not be successful in generating adequate revenues or commercializing aspects of its business model; Compugen's approach to the discovery of therapeutic products is based on its proprietary computational target discovery infrastructure, which is unproven clinically; Compugen does not know whether it will be able to discover and develop additional potential product candidates or products of commercial value; and the general market, political and economic conditions in the countries in which Compugen operates, including Israel; and the effect of the evolving nature of the recent war in Gaza between Israel and Hamas. These risks and other risks are more fully discussed in the "Risk Factors" section of Compugen's most recent Annual Report on Form 20-F as filed with the Securities and Exchange Commission (SEC) as well as other documents that may be subsequently filed by Compugen from time to time with the SEC. In addition, any forward-looking statements represent Compugen's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Compugen does not assume any obligation to update any forward-looking statements unless required by law.

Company contact:

Yvonne Naughton, Ph.D.
Head of Investor Relations and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071



Cision
Cision
View original content:https://www.prnewswire.com/news-releases/compugen-to-receive-10-million-milestone-payment-following-dosing-of-first-patient-in-astrazeneca-phase-3-rilvegostomig-trial-in-biliary-tract-cancer-302028318.html

SOURCE Compugen

Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement

https://finance.yahoo.com/news/compugen-regains-compliance-nasdaq-minimum-120000043.html

HOLON, Israel, Jan. 8, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that on January 4, 2024, it received a notification letter (the "Notification Letter") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it had regained compliance with the minimum bid price requirement set forth in the Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement").

As announced on November 3, 2023, the Company was notified that its ordinary shares failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by the Minimum Bid Price Requirement. To regain compliance with the Minimum Bid Price Requirement, the closing bid of the Company's ordinary shares needed to be at least $1.00 for a minimum of 10 consecutive business days.

The Notification Letter confirmed that the Company evidenced a closing bid price at or greater than the $1.00 per ordinary share minimum requirement for the last 10 consecutive business days from December 19, 2023 to January 3, 2024 and that the Company has regained compliance with the Minimum Bid Price Requirement.

Easy $ cgen down another -3% today

When you warn traders not to short that crazy stock… but they just have to…#tradingIsEasy pic.twitter.com/rTDwQ4MR3a— Modern_Rock (@modern_rock) December 19, 2023

Nah.

Pharma is horrible to hold on a risk reward basis through waiting for news.

The stock is selling off as someone is trying to get shares.

Once they get what they want, it will start bouncing.

There are a lot people that held and are up.

Easy to scare them out dropping from $2.50 to below $2.00

Today's deal sounds good, it's just that someone tried to get cheap shares.

It's best to find an entry on pullbacks on good pharma news because there is plenty to shakeout.

It's finding support for a push later.

Short it gap fill

CGEN hope for $1.67 new temp support previous resistance if not $1.46 if not $1.34 is a harder support level also

dilution tracker Major Developments
12/19/2023, 8:13:40 AM Gilead to Make $60 Million Upfront Payment and $30 Million in a Near Term Milestone Payment with a Total Deal Value of up to $848 Million

https://dilutiontracker.com/app/search/CGEN?a=dbb88c

Dosing of first patient in Phase 3 trial of rilvegostomig, a PD-1/TIGIT bispecific antibody, will trigger $10 million milestone payment from AstraZeneca
HOLON, Israel, Dec. 19, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced it will be eligible to receive a milestone payment of $10 million from AstraZeneca (LSE/STO/Nasdaq: AZN),

congrat$$$$

https://www.prnewswire.com/news-releases/compugen-will-be-eligible-to-receive-10-million-milestone-payment-upon-dosing-of-first-patient-in-astrazeneca-phase-3-rilvegostomig-trial-in-biliary-tract-cancer-302018835.html

https://finviz.com/quote.ashx?t=CGEN&ty=c&ta=1&p=d



https://dilutiontracker.com/app/search/CGEN?a=dbb88c

Conference call just started.
https://veidan.activetrail.biz/compugencorporateupdate19.12.23?action=thankyou

Compugen to Host Conference Call to Discuss Exclusive License Agreement with Gilead for COM503, Novel Immuno-Oncology Pre-Clinical Program Harnessing IL-18 Biology

https://finance.yahoo.com/news/compugen-host-conference-call-discuss-120500402.html

Conference call today, December 19, 2023, 8:30 AM ET to discuss the license agreement

HOLON, Israel, Dec. 19, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that it will host a conference call at 8:30 AM ET today, to discuss the exclusive license agreement with Gilead announced today, for the development and commercialization of its anti-IL-18 binding protein program including COM503, a pre-clinical potential first-in-class high affinity antibody targeting IL-18 binding protein with potential to treat multiple tumor types.

Conference Call Details

To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S., or +972-3-918-0644 internationally. The call will be available via live webcast through Compugen's website, located at the following link.

Following the live webcast, a replay will be available on the Company's website.

Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer

Dosing of first patient in Phase 3 trial of rilvegostomig, a PD-1/TIGIT bispecific antibody, will trigger $10 million milestone payment from AstraZeneca

HOLON, Israel, Dec. 19, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced it will be eligible to receive a milestone payment of $10 million from AstraZeneca (LSE/STO/Nasdaq: AZN), when the first patient is dosed in AstraZeneca's ARTEMIDE-Bil01 trial with rilvegostomig. Rilvegostomig is a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical-stage anti-TIGIT antibody, COM902. The ARTEMIDE-Bil01 trial is expected to recruit about 750 subjects in more than 20 countries with biliary tract cancer who will be randomized to receive rilvegostomig or placebo with investigator choice chemotherapy as adjuvant treatment after resection with curative intent.

"I am delighted to see the advancement of rilvegostomig into Phase 3 by AstraZeneca, a global leader in oncology," said Anat Cohen-Dayag, Ph.D., President, and Chief Executive Officer of Compugen. "I believe that the progress of the rilvegostomig clinical program in this Phase 3 trial along with the Phase 1 and 2 trials in additional indications, demonstrates the commitment to explore the potential of this bispecific antibody, where the TIGIT component is derived from our anti-TIGIT antibody COM902."

About the Compugen-AstraZeneca license agreement

In 2018, Compugen and AstraZeneca entered into an agreement by which Compugen provided an exclusive license to AstraZeneca to use Compugen's monospecific antibodies that bind to TIGIT, including COM902, for the development of bispecific and multispecific antibody products, excluding such bispecific and multispecific antibodies that also bind to PVRIG, PVRL2 and/or TIGIT. AstraZeneca is responsible for all research, development, and commercial activities. AstraZeneca has the right to create multiple products under this license. In addition to the $10 million milestone payment described here which Compugen will be eligible to receive on dosing of the first patient in the Phase 3 ARTEMIDE-Bil01 trial, Compugen has received a $10 million upfront payment, and an additional $15.5 million in milestone payments to date, all out of up to an aggregate milestone amount of $200 million that the Company is eligible to receive in development, regulatory and commercial milestones for the first product, as well as tiered royalties on future product sales. If additional bi- or multi-specific products are developed based on Compugen's monospecific antibodies that bind to TIGIT, additional milestones and royalties would be due to Compugen.

Further details about ARTEMIDE-Bil01 trial are available on ClinicalTrials.gov, identifier: NCT06109779.

Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program

https://finance.yahoo.com/news/gilead-compugen-announce-exclusive-license-120000324.html

– Gilead Will Have Exclusive Rights to Later Stage Development and Commercialization of Anti-IL18 Binding Protein Antibodies with Potential to Treat Various Tumor Types –

– Gilead to Make $60 Million Upfront Payment and $30 Million in a Near Term Milestone Payment with a Total Deal Value of up to $848 Million –

FOSTER CITY, Calif. & HOLON, Israel, December 19, 2023--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced an agreement with Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, headquartered in Holon, Israel, to exclusively license its potential first-in-class, pre-clinical antibody program against IL-18 binding protein, including the COM503 drug candidate.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231218814564/en/

Compugen utilizes its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing novel cancer immunotherapies. COM503 is a potential first-in-class, high affinity antibody which blocks the interaction between IL-18 binding protein and IL-18, thereby releasing natural IL-18 in the tumor microenvironment and inhibiting cancer growth.

"We are very pleased to add COM503 to our pipeline of investigational immuno-oncology therapies that have the potential to transform care for patients with cancer," said Flavius Martin, M.D., Executive Vice President, Research, Gilead Sciences. "We believe that this collaboration complements our strategy of developing modalities which promote immune-mediated tumor killing and may enable new combination therapies with programs in our growing oncology portfolio."

"We are delighted to enter into this collaboration with Gilead and believe that Gilead’s confidence in our differentiated approach to harness cytokine biology for cancer therapeutics speaks to the quality of our computational discovery capabilities as well as our ability to translate our novel discoveries into investigational drugs in the clinic and we look forward to working together to bring new treatment options to patients," said Anat Cohen-Dayag, Ph.D., President, and CEO at Compugen. "IL-18 is one of the rare cytokines which is naturally inhibited by an endogenous binding protein, presenting a unique opportunity to use a blocking antibody to increase the local concentrations of IL-18 within the tumor where it can potentiate anti-tumor immune responses, thereby potentially overcoming the limitations of systemically administered cytokines."

Terms of the Partnership

Under the terms of the agreement, Compugen will be responsible for the ongoing pre-clinical development and the future Phase 1 study of COM503. Thereafter, Gilead will have the sole right to develop and commercialize COM503.

Gilead will make Compugen an upfront payment of $60 million and $30 million in a near term milestone payment subject to IND clearance of COM503 expected in 2024. Compugen will also be eligible to receive up to an additional $758 million in future development, regulatory and commercial milestone payments, with a total deal value of $848 million. Compugen will also be eligible to receive single-digit to low double-digit tiered royalties on worldwide net sales.

Beginning in the first quarter of 2022, consistent with recent industry communications from the U.S. Securities and Exchange Commission (SEC), Gilead no longer excludes acquired IPR&D expenses from its non-GAAP financial measures. This transaction with Compugen is expected to reduce Gilead’s GAAP and non-GAAP 2023 EPS by approximately $0.03 - $0.05.

Wild

Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer

News coming?

Bought almost 8000 shares today have very high hopes for this stock.

Bump

I’ll be the first to admit I was wrong about where I saw the market value going for cgen. It appears that the horse is very strong with great lineage but it’s being ridden by a sub par jockey.

I feel like the pps settles @ $7-$9 until late 3rd early 4th Q. Then we see $5 or $40. Please be $40.

Per my boy Wang, “I figured why cgen has gotten smacked in the last week. So ark funds. The cathie wood fund that started this whole craze owns 29% of cgen. They had record outflows this week so they were forced to sell some stock. Ark was the firm that bought tesla when it was $100 and said it was going to $2000. They also own a huge chunk of BIDU. Stock fell from 350 to 280 this past week (similar selling to cgen)”

“Ark still owns a ton of cgen in all their different funds. Everything they invest in is next generation technology.”

Trump Covid?
it's the Chinese Virus.

:)

The new rating couldn’t have been timed worse. Jefferies and it’s analyst look foolish

New Analyst Rating---Jeffries puts a $25 target and buyout of CGEN imminent

Compugen assumed with a Buy at Jefferies Jefferies analyst Chris Howerton assumed coverage of Compugen with a Buy rating with a price target of $25, up from the firm's previous target of $20. The company's lead assets, alphaPVRIG and alphaTIGIT, are novel anti-cancer/immune-checkpoint drugs with evidence that supports pathways for broad tumor types, suggesting each drug could become "Keytruda-like," Howerton tells investors.

Read more at:
https://thefly.com/n.php?id=3174816

Recovered nicely from Trump Covid market reaction. Looking forward to positive test results any day now!

Decided to take a position today as it was pushing through the 16's. Looks promising as a long term hold. GLTA

"Compugen’s (CGEN) early-stage study is evaluating the safety, tolerability and preliminary antitumor activity of COM701 (the company’s first-in-class anti-PVRIG antibody) in combination with Bristol Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo (nivolumab) and BMS-986207."

https://finance.yahoo.com/news/compugen-starts-dosing-early-stage-053529308.html


I can see CGEN at $60-$75 per share min next year if a buyout occurs. I know a lot of heavy hitters are watching this and a working partnership with Bristol Myers Squibb, a 140 billion dollar beast is very encouraging.

New closing high at $19.45. Hopefully we will see $20 soon. Market cap is starting to get pretty significant.

All I have to say is wow!! This could really be a life changer. I really believe this could be a $60-80 stock in a year.

Wall Street rumors scaring some weak hands. CGEN could bounce really fast with next patient test results. CGEN also being courted for a buyout by this time next year.

Great day here! Think we may finally be getting out of the trading channel we’ve been stuck in...

Compugen is the company everyone in Pharma will be talking about this year. Already a 7 plus bagger and climbing from its 52 week low.

Would love to see an updated CGEN chart. So much going on leading to next week's big conference.

Compugen initiated with a Buy at Roth Capital Roth Capital analyst Tony Butler initiated coverage of Compugen with a Buy rating and $28 price target. The company has discovered and is developing immune checkpoint therapeutic drugs to address the unmet needs in a multitude of cancer indications, Butler tells investors in a research note. Compugen's lead asset COM701, combined with the second asset COM902, has shown evidence of efficacy in tumors that are immunologically "cold," or immune-suppressed, where currently approved checkpoint inhibitors have shown little or no efficacy, contend the analyst.

Read more at:
https://thefly.com/landingPageNews.php?id=3076556

Roth Capital just gave a price target of $28...BOOM!!!

Big report coming out on April 27th!! Market knows this company is a monster in the making.

$CGEN ramping up for the presentation and buyout rumors it seems.

Hit $14 in AH last evening.

In a way I’m glad pps is down. Even w Covid 19 the stick was rising prior to dilution. CGEN will survive and do great things. You want to invest in crap or a company that cures cancer?

* * $CGEN Video Chart 03-10-2020 * *

Link to Video - click here to watch the technical chart video

Test confirmed no toxic effects to patients and in many cases complete tumor reduction. Mic drop..sit back and watch this one sky rocket!

* * $CGEN Video Chart 02-06-2020 * *

Link to Video - click here to watch the technical chart video

Over $9.00 boom

Respectfully, good times are now rolling for CGEN. I found this company in 2000. Yes 2000!!! CGEN has survived for 20 years (human years). The investment in developing their drug discovery database will help people. This is why my family and many continue to invest. If you buy this stock you will buy into something real, something that will benefit mankind, something that is proven.

CGEN could have multiple cancer treatments approved by FDA this time next year.

Lonely message board here. More posters on Yahoo Finance. I’ve quadrupled my holdings in CGEN dice December and starting to feel pretty good about it.

Over $7 boom.

Massive upside here.